RxDoctor Payments Data

Sol Velezcortes, MD

Internal Medicine · Boynton Beach, FLNPI 1760469332

Payments from drug & device makers

$7,888in general payments, 2019–2025

Across 355 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$669
  • Lilly USA, LLC$493
  • Tanabe Pharma America, Inc.$451
  • Avanir Pharmaceuticals, Inc.$451
  • Eisai Inc.$390
  • Argenx US, Inc.$388
  • plus $5K from 44 others

What the payments were for

  • Speaking & faculty fees$821%
  • Food & beverage$7,78699%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,888 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$337,644
Medicare patients
173
Services billed
3,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$111,093
EliquisApixaban44$48,284
MounjaroTirzepatide37$37,151
OzempicSemaglutide19$32,350
JardianceEmpagliflozin30$29,041
XareltoRivaroxaban22$24,921
Breo ElliptaFluticasone/Vilanterol26$21,871
MyrbetriqMirabegron15$15,332
TrulicityDulaglutide11$10,581
Rivastigmine29$7,365
Rosuvastatin Calcium267$5,064
Novolog FlexpenInsulin Aspart13$3,268
Donepezil Hcl67$2,854
SynthroidLevothyroxine Sodium39$2,454
Atorvastatin Calcium172$2,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$669$111,09383 claims
PfizerEliquis, Paxlovid$65$49,71455 claims
Lilly USA, LLCMounjaro, Trulicity$493$47,73248 claims
Novo NordiskOzempic$25$32,35019 claims
Johnson & JohnsonXarelto$265$24,92122 claims
GSKBreo Ellipta$102$21,87126 claims
AbbVieSynthroid$287$2,45439 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$80$1,237119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →